Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination therapy with AK104 and AK112 for recurrent ovarian cancer
NCT06560112Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, ivonescimab in ovarian cancer, sponsored by Akeso, Inc.. Started Nov 2024; status: recruiting.
02
Drugs
cadonilimabivonescimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06560112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560112.